1. Home
  2. MRK vs SCLXW Comparison

MRK vs SCLXW Comparison

Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRK
  • SCLXW
  • Stock Information
  • Founded
  • MRK 2000
  • SCLXW N/A
  • Country
  • MRK United States
  • SCLXW United States
  • Employees
  • MRK N/A
  • SCLXW 31
  • Industry
  • MRK Biotechnology: Pharmaceutical Preparations
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRK Health Care
  • SCLXW Health Care
  • Exchange
  • MRK Nasdaq
  • SCLXW Nasdaq
  • Market Cap
  • MRK 218.8B
  • SCLXW N/A
  • IPO Year
  • MRK N/A
  • SCLXW N/A
  • Fundamental
  • Price
  • MRK $85.64
  • SCLXW $0.26
  • Analyst Decision
  • MRK Buy
  • SCLXW
  • Analyst Count
  • MRK 15
  • SCLXW 0
  • Target Price
  • MRK $105.29
  • SCLXW N/A
  • AVG Volume (30 Days)
  • MRK 10.2M
  • SCLXW 4.0K
  • Earning Date
  • MRK 10-30-2025
  • SCLXW 03-07-2025
  • Dividend Yield
  • MRK 3.78%
  • SCLXW N/A
  • EPS Growth
  • MRK 58.06
  • SCLXW N/A
  • EPS
  • MRK 7.56
  • SCLXW N/A
  • Revenue
  • MRK $64,235,000,000.00
  • SCLXW $55,152,000.00
  • Revenue This Year
  • MRK $1.82
  • SCLXW N/A
  • Revenue Next Year
  • MRK $5.10
  • SCLXW N/A
  • P/E Ratio
  • MRK $11.35
  • SCLXW N/A
  • Revenue Growth
  • MRK 1.68
  • SCLXW 22.02
  • 52 Week Low
  • MRK $73.31
  • SCLXW $0.18
  • 52 Week High
  • MRK $105.07
  • SCLXW $0.18
  • Technical
  • Relative Strength Index (RSI)
  • MRK 51.03
  • SCLXW 55.39
  • Support Level
  • MRK $82.01
  • SCLXW $0.18
  • Resistance Level
  • MRK $88.30
  • SCLXW $0.30
  • Average True Range (ATR)
  • MRK 2.01
  • SCLXW 0.06
  • MACD
  • MRK -0.35
  • SCLXW 0.02
  • Stochastic Oscillator
  • MRK 53.54
  • SCLXW 80.64

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: